Now showing items 1-20 of 1992

      Subject
      1 (3 chlorophenyl) 3 [4 (pyrrolidin 1 yl)phenyl]prop 2 en 1 one; 1 (3 methoxyphenyl) 3 [4 (piperidin 1 yl)phenyl]prop 2 en 1 one; 1 (3 methoxyphenyl) 3 [4 (pyrrolidin 1 yl)phenyl]prop 2 en 1 one; 1 (benzo[d][1,3]dioxol 5 yl) 3 [4 (pyrrolidin 1 yl)phenyl]prop 2 en 1 one; 1 [4 (methylsulfonyl)phenyl] 3 (4 morpholinophenyl)prop 2 en 1 one; 1 [4 (methylsulfonyl)phenyl] 3 [4 (piperidin 1 yl)phenyl]prop 2 en 1 one; 1 [4 (methylsulfonyl)phenyl] 3 [4 (pyrrolidin 1 yl)phenyl]prop 2 en 1 one; 1 [4 (methylthio)phenyl) 3 [4 (piperidin 1 yl)phenyl]prop 2 en 1 one; 1 [4 (methylthio)phenyl] 3 (4 morpholinophenyl)prop 2 en 1 one; 1 [4 (methylthio)phenyl] 3 [4 (pyrrolidin 1 yl)phenyl]prop 2 en 1 one; 3 (4 morpholinophenyl) 1 [4 (piperazin 1 yl) phenyl)prop 2 en 1 one; 3 [4 [bis(2 chloroethyl)amino]phenyl] 1 (2 methoxyphenyl)prop 2 en 1 one; 3 [4 [bis(2 chloroethyl)amino]phenyl] 1 [4 (methylsulfonyl)phenyl]prop 2 en 1 one; antineoplastic agent; chalcone derivative; chlormethine; colchicine; estrogen; morpholine; P cadherin; paclitaxel; piperidine derivative; protein Bax; protein bcl 2; pyrrolidine derivative; unclassified drug; uvomorulin; vasculotropin receptor 2; [3 [4 [bis(2 chloroethyl)amino]phenyl] 1 (3 methoxyphenyl)prop 2 en 1 one]; chalcone; nitrogen; angiogenesis; animal cell; animal experiment; animal model; antineoplastic activity; antiproliferative activity; apoptosis; Article; cancer inhibition; cell invasion; cell migration; chorioallantois; clinical effectiveness; clinical evaluation; colony formation; comparative study; concentration response; controlled study; cytotoxicity; down regulation; drug design; drug efficacy; drug identification; drug synthesis; epithelial mesenchymal transition; G2 phase cell cycle checkpoint; human; human cell; IC50; in vivo study; MCF-7 cell line; MDA-MB-231 cell line; MDA-MB-468 cell line; mouse; nonhuman; triple negative breast cancer; tumor xenograft; upregulation; animal; cell cycle checkpoint; cell proliferation; cell survival; chemical structure; chemistry; dose response; drug effect; drug screening; experimental mammary neoplasm; female; molecular model; nude mouse; pathology; structure activity relation; synthesis; triple negative breast cancer; tumor cell culture; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Nitrogen; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured [1]
      1 [4 (methylsulfonyl)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one; 1 [4 (methylthio)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one; 1 [4 (methylthio)phenyl] 3 [3 (trifluoromethyl)phenyl]prop 2 en 1 one; 3 (2 methoxyphenyl) 1 [4 (methylsulfonyl)phenyl]prop 2 en 1 one; 3 (2,5 dimethoxyphenyl) 1 [4 (methylsulfonyl)phenyl]prop 2 en 1 one; 3 (6 bromobenzo[d][1,3]dioxol 5 yl) 1 [4 (methylsulfonyl)phenyl]prop 2 en 1 one; 3 (6 bromobenzo[d][1,3]dioxol 5 yl) 1 [4 (methylthio)phenyl]prop 2 en 1 one; 3 (6 bromobenzo[d][1,3]dioxol 5 yl) 1 [4 (piperazin 1 yl)phenyl]prop 2 en 1 one; 3 (benzo[b]thiophen 2 yl) 1 (3 methoxyphenyl)prop 2 en 1 one; 3 (benzo[b]thiophen 2 yl) 1 (3,4,5 trimethoxyphenyl)prop 2 en 1 one; 3 (benzo[b]thiophen 2 yl) 1 (benzo[d][1,3]dioxol 5 yl)prop 2 en 1 one; 3 (benzo[b]thiophen 2 yl) 1 [4 (methylsulfonyl)phenyl]prop 2 en 1 one; 3 (benzo[b]thiophen 2 yl) 1 [4 (methylthio)phenyl]prop 2 en 1 one; 3 [2 fluoro 4 (trifluoromethyl)phenyl] 1 [4 (methylthio)phenyl]prop 2 en 1 one; antineoplastic agent; B Raf kinase; beta catenin; chalcone derivative; fascin; paclitaxel; protein Bax; protein bcl 2; unclassified drug; uvomorulin; vimentin; chalcone derivative; KRAS protein, human; protein p21; antiangiogenic activity; antineoplastic activity; apoptosis; Article; BRAF gene; cancer inhibition; cell adhesion; cell cycle; cell viability; colony formation; colorectal cancer; controlled study; down regulation; drug design; drug effect; drug efficacy; drug potency; drug potentiation; drug screening; drug selectivity; drug synthesis; epithelial mesenchymal transition; gene mutation; GI50; HCT 116 cell line; HT-29 cell line; immortalized cell line; in vitro study; in vivo study; LoVo cell line; metastasis; migration inhibition; oncogene K ras; priority journal; proapoptotic activity; process optimization; tumor invasion; tumor suppressor gene; tumor vascularization; upregulation; cell motion; cell proliferation; chemistry; colorectal tumor; genetics; human; tumor cell line; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chalcones; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Humans; Proto-Oncogene Proteins p21(ras) [1]
      16s rDNA [1]
      16S rRNA sequencing [2]
      16S sequencing [1]
      2018 [1]
      25-hydroxyvitamin D [1]
      3D bioprinting [1]
      3T3-L1 cell adipocytes [1]
      4-mercaptophenol [1]
      50-UTR [1]
      \Urine [1]
      A-PRF [1]
      AAA (Abdominal Aortic Aneurysm) [1]
      Abdominal aortic aneurysm [2]
      abdominal aortic aneurysm [1]
      Abdominal aortic aneurysm (AAA) [1]
      Abdominal Infection [1]
      abdominal pain; adult; Article; chill; comorbidity; comparative study; coronavirus disease 2019; coughing; cross-sectional study; disease association; female; fever; headache; human; major clinical study; male; miscellaneous named groups; myalgia; non vaccinated patient; observational study; Qatar; smoking; smoking cessation; sore throat [1]
      abdominal subcutaneous fat [1]